Flow Neuroscience
PrivateLast Round
Series A
Aug 10, 2021
Total Funding Raised
$10.1M
Company Overview
Flow Neuroscience operates in Healthcare & Life Sciences and is based in Malmö. Its latest recorded funding round was a Series A round in August 2021.
Flow Neuroscience is a medical technology company that develops a non-invasive, at-home brain stimulation headset and companion mobile application for the treatment of major depressive disorder.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Mental Health, Telemedicine, D2C Brands
Business Model
B2C
Customer Profile
Hardware Sales, Hardware + Subscription
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Flow Neuroscience Comparables
Compare Flow Neuroscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mave Health | 88% | |
| Neurolief | 84% | |
| Sooma | 84% |
For institutional investors. Book with your work email.
Flow Neuroscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 10, 2021 | ||||
| VC Round | Jul 23, 2019 | ||||
| Seed | Jan 25, 2018 | ||||
| Accelerator | Sep 15, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Flow Neuroscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Khosla Ventures | VC Round, Series A, Seed |
| Zühlke Ventures | Series A |
| Redstone VC | Series A |
| Schox Patent Group | Series A |
| SOSV | Seed |
| HAX | Accelerator, Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 23, 2019
$2M round led by Khosla Ventures.
- Jan 25, 2018
$1.1M round led by Khosla Ventures.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesSep 16, 2026
Flow Neuroscience makes FL-100, the first FDA-approved at-home tDCS treatment for depression, available by prescription across the United States on Sep 16th '26 for clinician-supervised treatment of eligible adults with moderate to severe major depressive disorder.
For institutional investors. Book with your work email.
Flow Neuroscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Flow Neuroscience's valuation, stock price, and market status.
Is Flow Neuroscience a public or private company?
Flow Neuroscience is a private company.
What is the current stock price of Flow Neuroscience?
Flow Neuroscience is a private company, so its shares have no public market price. Caplight tracks Flow Neuroscience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Flow Neuroscience worth (valuation)?
Valuation information for Flow Neuroscience is not publicly available.
Can I buy Flow Neuroscience stock?
Flow Neuroscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Flow Neuroscience's last funding round?
Flow Neuroscience's most recent funding round was Series A on August 10, 2021.
Who are the main investors in Flow Neuroscience?
Key investors in Flow Neuroscience include Khosla Ventures.
Will Flow Neuroscience IPO soon?
No public IPO plans have been announced for Flow Neuroscience.
How can I track Flow Neuroscience secondary market activity?
Caplight tracks bids, offers, and trades in Flow Neuroscience's shares on secondary markets.